Parabilis Medicines, Inc.

Contributing Author

Recent Articles by Parabilis Medicines, Inc.

7 hours	Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates PBLS -6.56% GlobeNewswire
Nov-03	Parabilis Medicines to Participate in Upcoming November Investor Conferences PBLS +7.34% GlobeNewswire
Oct-24	Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors PBLS GlobeNewswire
Oct-19	Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026 PBLS +11.43% GlobeNewswire
Oct-14	Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis PBLS GlobeNewswire
Sep-01	Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference PBLS GlobeNewswire
Aug-25	Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors PBLS GlobeNewswire
Aug-13	Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates PBLS GlobeNewswire
Jun-11	Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares PBLS PBLS -10.06% GlobeNewswire
Jun-09	Parabilis Medicines Announces Pricing of Upsized Initial Public Offering PBLS GlobeNewswire